Vis enkel innførsel

dc.contributor.authorSommen, Silke Lauren
dc.contributor.authorHavdal, Lise Beier
dc.contributor.authorSelvakumar, Joel Pradeepkumar
dc.contributor.authorEinvik, Gunnar
dc.contributor.authorLeegaard, Truls Michael
dc.contributor.authorLund-Johansen, Fridtjof
dc.contributor.authorMichelsen, Annika Elisabet
dc.contributor.authorMollnes, Tom Eirik
dc.contributor.authorStiansen-Sonerud, Tonje
dc.contributor.authorTjade, Trygve Olav
dc.contributor.authorWyller, Vegard Bruun Bratholm
dc.contributor.authorLund-Berven, Lise
dc.date.accessioned2023-02-22T09:31:39Z
dc.date.available2023-02-22T09:31:39Z
dc.date.created2023-02-17T10:49:25Z
dc.date.issued2022
dc.identifier.citationFrontiers in Immunology. 2022, 13:1081718 1-12.en_US
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/11250/3053067
dc.description.abstractIntroduction: Both public and scientific attention have shifted from the acute COVID-19 illness to the chronic disability experienced by a proportion of COVID-19 convalescents. Post COVID-19 condition, a term used for long-lasting symptoms after COVID-19, can affect individuals across all disease severity and age groups. Data on post-COVID-19 symptomatology, epidemiology and pathophysiology in adolescents and young adults are scarce. To date, little is known on the immunological and pulmonary trends in these patients after COVID-19. This study investigated immunological markers and pulmonary function in non-hospitalized patients in this group at 6 months after initial mild COVID-19 infection. Methods: Non-hospitalized SARS-CoV-2 positive (n = 405) and SARS-CoV-2 negative (n = 111) adolescents and young adults (aged 12-25 years) were followed prospectively for six months after SARS-CoV-2 PCR testing. At baseline and at six months follow-up, all participants underwent an assessment including clinical examination, questionnaires, spirometry, and blood sampling. Cross-sectional comparisons of blood biomarkers; including white blood cell counts, CRP, GDF-15, a 27-multiplex cytokine assay, complement activation products and SARS-CoV-2 antibodies; and spirometry measures were performed after classification of all participants according to their COVID-19 status and adherence to post-COVID-19 case criteria. Associations between biomarkers and COVID-19 symptoms were explored. Results: No difference in pulmonary function was detected between the groups. COVID-19 convalescents had higher levels of chemokines eotaxin, MCP-1 and IP-10 than non-infected controls. The increase was modest and not associated with long-lasting COVID-19 symptoms. Discussion: Elevated inflammatory mediators were found in adolescents and young adults six months after mild COVID-19, but there was no association with post-COVID-19 condition.en_US
dc.language.isoengen_US
dc.publisherFrontiers Mediaen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleInflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19en_US
dc.title.alternativeInflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19en_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-12en_US
dc.source.volume13:1081718en_US
dc.source.journalFrontiers in Immunologyen_US
dc.identifier.doi10.3389/fimmu.2022.1081718
dc.identifier.cristin2126909
dc.relation.projectNorges forskningsråd: 223255en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal